Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction - Wikidata - wikimedia - TriplyDB

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

http://www.wikidata.org/entity/Q35208151

about

Targeted therapy for advanced gastric cancer: A review of current status and future prospects Targeting receptor tyrosine kinases in gastric cancer Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer.Targeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Sex difference in EGFR pathways in mouse kidney-potential impact on the immune system Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.Clinicopathological features and outcomes of patients with gastric cancer: a single-center experience.New and emerging combination therapies for esophageal cancer.Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.Targeted therapy for gastric cancer--current status.Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.The role of epidermal growth factor receptor in prognosis and treatment of gastric cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.The role of targeted therapy for gastrointestinal tumors.Targeted therapy in gastric cancer.Biomarkers and novel agents in esophago-gastric cancer: are we making progress?Update on Gastroesophageal Adenocarcinoma Targeted Therapies.Current advances in targeted therapies for metastatic gastric cancer: improving patient care.Targeted therapy in esophageal cancer.Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.Novel Targeted Therapies for Esophagogastric Cancer.HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma.The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study.New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels.Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR amplified gastroesophageal adenocarcinoma.Current therapeutic landscape for advanced gastroesophageal cancers.Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.What's New in Gastric Cancer: The Therapeutic Implications of Molecular Classifications and Future Perspectives

P2860

Q26774138-20DCF06E-16AB-4A6E-8A58-E8FFCCF7A52C Q27013050-9580752D-7B0B-45B0-BA88-3B8ED66CEFC9 Q28079362-4D3B076D-89B8-46BC-B123-CAF0E8EE09FE Q33709855-C56DEF5D-75F6-433E-8C30-FE15AB9BAD08 Q34158454-0F10ABA1-C6CB-4606-8B71-145AABCD3DD6 Q35032328-BDEC9259-65E2-4C5C-8AE2-898714CC9616 Q35863874-F5A9D830-4DBC-4AE7-9423-2A59EF7A262B Q36202764-4EE1D2AF-F0F5-49C6-9103-6AD17C01B30E Q36205151-82A59BBC-BC99-4DF3-8799-5E4195217DD6 Q36467960-F4EC4682-235B-4F2E-970C-13A89C0DE1E3 Q36547753-73E8A425-BDC0-417F-A777-A37E39709485 Q36567393-2394C4E8-B6AF-476B-B518-D30CF23043F7 Q36770478-39EE42DC-5468-4025-BDEC-83A77F94D3B0 Q36996728-7754B6C8-AC57-4F81-A41E-FB80BB6D5702 Q37038482-E2F58029-5C57-4A5E-82F2-C77C89F50F44 Q38019898-2E9A4B34-91DF-42F9-B19B-71ACE648CCA3 Q38073827-21280094-F021-4A0F-989F-604CE8E46BB4 Q38177325-3845C563-046A-48AD-BF15-0FBEB6CF1722 Q38221886-A6EA8732-39E0-4254-AD0B-427286A85A10 Q38222585-B60DFD9C-38C4-4444-9897-CAF61C409DBA Q38364292-9C8D41C2-2AF1-428E-BAB1-1B7DE66D044E Q38575013-0B22AD1E-EFFE-4C13-93E2-8450175C7B32 Q38684349-C951573D-F727-4BB6-B0FC-F1DB35E0CCA6 Q38720829-642F43BF-A43A-4A2B-A7EF-98EEABE14F63 Q38741042-3A845EBD-BE20-4DDF-8F7B-5A668C584A6D Q38939088-A33DAE21-0C29-47DB-AA24-25B40B1FA22C Q38970911-8B97827D-A6F0-4C24-A600-F9C0BEC01A65 Q39171565-3869A23A-6FED-48A2-89FF-DC19D362FB51 Q41839228-5054F20C-8DD3-4AE3-A154-A713A45285A2 Q45202800-37C937F5-B7CF-4640-AEA6-867FEE5A141A Q47621738-21F71D2D-499B-4230-B48F-0D4BBF969D7C Q49961144-8F6836E8-ACED-4BD5-A46C-9E25D590E1B9 Q52581752-A7CE19B6-3246-443D-A0A7-67FF3BE8CCB5 Q52682256-46C88D8B-CF3C-46BB-B204-60B778F7BF22 Q57159608-A8C5FE60-AAD8-41B1-A771-5599CC08D91B

P2860

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

http://www.wikidata.org/entity/Q35208151

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@ast

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@en

type

label

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@ast

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@en

prefLabel

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@ast

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@en

P1433

Q35208151-3A461364-E61E-43C1-8316-5EB1CF663BBB

P1476

Q35208151-6D519B49-4CED-41D0-AE9D-BF889B99659B

P2093

Q35208151-3BD7B60B-E03F-4B31-A66C-3834B8E57852

Q35208151-580C010B-FD2D-4F7E-B8C4-E6D8BCB9C4D9

Q35208151-70AC34FA-EA4F-44FD-8633-2C7F45BA301C

Q35208151-75ECBA83-42F2-459E-BD66-9F4F2D642A63

Q35208151-9AC59A8A-4F31-4501-84A3-ADDC21CB5885

Q35208151-9F120BFD-A521-4817-B211-0F0EEF8DF223

Q35208151-A43D1D3D-C7FA-4175-8781-4D743218369F

Q35208151-CCC1AF9A-DA57-40B8-BCAD-656846DBED4D

Q35208151-D14C0801-F82E-4E65-84ED-BE033D247A82

Q35208151-F776C827-6B06-47C6-8945-75B9CD7C25C0

P2860

Q35208151-05AA2B59-4643-4C84-8C4D-C3B3B02FAF98

Q35208151-0881B88C-DFDF-4A01-B21C-D27A958EEDAA

Q35208151-101E17F5-FB2D-4D39-AE8B-0D2A99497748

Q35208151-1C1F7D50-D58F-4AE7-B68B-11249FC74B31

Q35208151-1CC6E292-A49C-4B08-8B27-7590C0BDFBAF

Q35208151-25CA3894-9EE9-4B3F-AD76-67C96086DE71

Q35208151-2D8AAB7A-9F9E-4A91-9D57-0EFB6AB559BE

Q35208151-33A4C517-AD45-4E29-A29F-E5127F6FB6C2

Q35208151-340085F4-9F51-4DE6-ABFF-084DB6864519

Q35208151-39FE55FA-E952-403D-A382-BE6E12C55886

P2888

Q35208151-8216BDFA-5ABC-4015-BFFF-FC29F299D85D

P304

Q35208151-71D5C69C-5578-4EF5-8427-6067E1AA0017

P31

Q35208151-8AFB6247-47EB-43E0-823F-F768F3A15C40

P356

Q35208151-06593447-401A-455E-B14E-F6E77FCEFCA5

P407

Q35208151-260504FF-192D-4415-9D9C-CD6F5127EC61

P433

Q35208151-84FEFFE3-E41D-43B7-8B15-C97C30F5000A

P478

Q35208151-DFBA9785-B9A8-4A2C-A7F4-8E970EE89791

P577

Q35208151-558BB7DC-E9F6-499A-81D6-DC92AAC1558D

P5875

Q35208151-B159EAF9-C394-4DEA-A307-5A90B01C9F9D

P698

Q35208151-F9EDE91D-1A66-47CA-948C-0ED94499A667

P921

Q35208151-2936EB1A-04A9-4332-A09D-D462268132D1

Q35208151-76BECAE4-71C2-4516-A125-D0B6036408C7

P932

Q35208151-708A7281-14F9-496E-B562-A1CD444BF659

P356

P1433

British Journal of Cancer

P1476

Phase II trial of modified FOL ...... nd gastro-oesophageal junction

@en

P2093

B DiCarlo

http://www.w3.org/2001/XMLSchema#string

D J Park

http://www.w3.org/2001/XMLSchema#string

H-J Wang

http://www.w3.org/2001/XMLSchema#string

J R Hecht

http://www.w3.org/2001/XMLSchema#string

K M Dao

http://www.w3.org/2001/XMLSchema#string

L-S Lin

http://www.w3.org/2001/XMLSchema#string

N Ryba

http://www.w3.org/2001/XMLSchema#string

R Elashoff

http://www.w3.org/2001/XMLSchema#string

R Patel

http://www.w3.org/2001/XMLSchema#string

Z A Wainberg

http://www.w3.org/2001/XMLSchema#string

P2860

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Cancer statistics, 2009

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

P2888

P304

760-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2011.280

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51542240

http://www.w3.org/2001/XMLSchema#string

P698

21811258

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3171005

http://www.w3.org/2001/XMLSchema#string